Defitelio (defibrotide) - Important Safety Information from Gentium S.r.l. as approved by the HPRA (13.06.2022)

Notice type: 3rd Party Publications

Date: 14/06/2022

 

Problem Or Issue:
Important Safety Information from Gentium S.r.l. regarding Defitelio (defibrotide): Do not use for prophylaxis of veno-occlusive disease (VOD) after post-hematopoietic stem-cell transplantation (HSCT)

Important Safety Information - Defitelio (defibrotide)


« Back